medigraphic.com
ISSN 1817-5996 (Electronic)

2012, Number 20

<< Back Next >>

Rev Cub de Reu 2012; 14 (20)

Training of new bone and ankylosing spondylitis

Suárez MR, Molinero RC, Prada HD, López MAM, Lemagne PY

Language: Spanish
References: 34
Page:
PDF size: 140.27 Kb.


ABSTRACT

The training of new bone in the ankylosing spondylitis is one of the subjects of greater interest in the pathogeny of the illness and to the cual has loaned him big attention in the transcurso of the last years, revolutionised the initial opinion of the pathogeny of the illness and that the treatment of the inflammation of the entesis with the anti TNF would attain the control of the training of new bone (sindesmofitos and the anquilosis osseous) that produces in the ankylosing spondylitis. It is real and is showed that the treatment with anti TNF practically attain to control the process inflamatorio, but does not occur the same with the training of new bone in the espondilitis anquilosante.


REFERENCES

  1. Yang Mei, Faming Pan, Jing Gao, Rui G. Increased serum IL-17 and IL-23 in the patient with ankylosing spondylitis. Clin Rheumatol 2011; 30: 269- 73.

  2. Aguado Acín P. Lo que el clínico debe saber sobre los mecanismos de conexión entre la inflamación y la formación de hueso. ¿Es suficiente el bloqueo de la inflamación para prevenir la osificación? Reumatol Clin.2010; 6(S1):28–32.

  3. Mc Gonagle D, Wakefield RJ, Tan AL, D’Agostino M A,Toumi H, Hayashi K. Distinct topography of erosion and new bone formation in achilles tendon enthesitis. Implications for understanding the link between inflammation and bone formation in spondylarthritis.Arthritis Rheum.2008; 58: 2694-9.

  4. Boyle W J,Simonet WS,Lacey DL. Osteoclast differentiation and activation. Nature. 2003; 423: 337- 42.

  5. Hofbauer LC, Schoppet M. Clinical implications of the Osteoprotegerin/RANKL/RANK System for bone and vascular diseases. J AMA. 2004; 292: 490- 5.

  6. Braun J, Sieper J: Ankylosing spondylitis. Lancet 2007, 369: 1379- 90.

  7. Walsh C,Gravallese EM. Bone loss in inflammatory arthritis: mechanisms and treatment strategies.Curr Opin Rheumatol. 2004; 16: 419– 27.

  8. Vandooren B, Cantaert T, Noodenbos T, Tak PP, Baeten D. The abund synovial expression of the RANKL/RANK/Osteoprotegerin system in peripheral spondyloarthritis is partially disconnected from inflammation. Arthritis Rheum. 2008; 58: 718– 29.

  9. van der Heijde D, Landewe R, Einstein S. Radiographic progression of ankylosingspondylitis after up to two years of treatment with etanercept.Arthritis Rheum 2008, 58:1324- 31.

  10. Van der Heijde D, Landewe R, Baraliakos X.: Radiographicfindings following two years of infliximab therapy inpatients with ankylosing spondylitis. Arthritis Rheum 2008, 58: 3063- 70.

  11. Van der Heijde D, Landewe R, Maksymowych W. Adalimumab (HUMIRA®) therapy for Ankylosing spondylitisover 2 years does not demonstrate inhibition of radiographicprogression compared with a historical control group. Arthritis Rheum 2008, 58: 413-22.

  12. Wanders A, van der Heijde D, Landewe R, Behier JM, Calin A, Olivieri I, Zeidler H, Dougados M: Nonsteroidal antiinflammatorydrugs reduce radiographic progression in patients with ankylosingspondylitis: a randomized clinical trial. Arthritis Rheum. 2005; 52: 1756- 65.

  13. Raisz LG. Pathogenesis of osteoporosis: concepts, conflicts and prospects. J Clin Invest. 2005; 115: 3318– 25.

  14. Tam, LS, Gu, J, David Y.Pathogenesis of ankylosing spondylitis. Nat. Rev. Rheumatol.2010; 6: 399–405.

  15. Lories, R. J, Luyten, F. P. Bone morphogenetic protein signaling in joint homeostasis and disease. Cytokine Growth Factor Rev. 2005; 16: 287– 98.

  16. Winkler, D. G. Noggin and sclerostin bone morphogenetic protein antagonists form a mutually inhibitory complex. J. Biol. Chem. 2004; 279: 36293– 98.

  17. De Vlam K, Lories RJ, Luyten FP: Mechanisms of pathologic new bone formation. Curr Rheumatol Rep. 2006; 8:332-7.

  18. Macsai CE, Foster BK, Xian CJ: Roles of Wnt signaling in bone growth, remodeling, skeletal disorders and fracture repair. J Cell Physiol. 2008; 215: 578- 87.

  19. Lories R.J.U, Luyten F. P, de Vlam K. Progres in spondiloarthritis. Mechanisms of new bone formation in spondyloarthritis. Arthritis Research & Therapy. 2009; 11: 221-28.

  20. Lories RJU, Derese I, Luyten FP: Modulation of Bone Morphogenetic Protein signaling inhibits the onset and progression of ankylosing enthesitis. J Clin Invest. 2005; 115:1571- 79.

  21. Schett, G., Zwerina, J, David, J. P. The role of Wnt proteins in arthritis. Nat. Clin. Pract.Rheumatol. 2008; 4: 473- 80.

  22. Chen Y, Whetstone HC, Youn A. Beta-catenin signaling pathway is crucial for bonemorphogenetic protein 2 to induce new bone formation. J BiolChem 2007, 282:526-33.

  23. Tamamura Y, Otani T, Kanatani N, Developmental regulation of Wnt/betacateninsignals is required for growth plate assembly, cartilageintegrity, and endochondral ossification. J Biol Chem. 2005; 280: 19185- 95.

  24. Van Bezooijen, R. L. Sclerostin is an osteocyte-expressed negative regulator of bone formation, but not a classical BMP antagonist. J. Exp. Med. 2004; 199: 805-14.

  25. Diarra D, Stolina M, Polzer K,Zwerina J, Ominsky MS, Dwyer D,etal. Dickkopf-1 is a master regulator of joint remodeling. Nat Med. 2007; 13: 156- 63.

  26. Daoussis, D. Evidence that Dkk-1 is dysfunctional in ankylosing spondylitis. ArthritisRheum. 2010; 62: 150- 58.

  27. Appel H, Ruiz-Heiland G, Listing J, Zwerina J,Herrmann M, Mueller R, et al. Altered skeletal expression of sclerostin and its link to radiographic progression in ankylosing spondylitis Artritis Rheum. 2009; 60: 3257-62.

  28. Maksymowych, W. P. Disease modification in ankylosing spondylitis. Nat. Rev. Rheumatol. 2010; 6: 75- 81.

  29. Lories R J U, DereseI ,De Bari C, Luyten FP. Evidence for uncoupling of inflammation and joint remodeling in a mouse model of spondylarthritis. Arthritis & Rheum.2007; 56:489-97.

  30. Andreu, José Luis, Teresa Otón, and Jesús Sanz. "Terapia anti-TNFα en espondilitis anquilosante: control sintomático y modificación del daño estructural." Reumatología Clínica 7.1 (2011): 51-55.

  31. Maksymowych WP, Chiowchanwisawakit P, ClareT, Pedersen SJ, Ostergaard M, Lambert RGW. Inflammatory lesions of the spine of magnetic resonance imaging predict the development of new syndesmophytes in ankylosing spondylitis. Evidence of a relationship between inflammation and new bone formation. Arthritis Rheum.2009; 60:93–102.

  32. Visvanathan S, van der Heijde D, Deodhar A, Wagner C, Baker DG, Han J, Braun J: Effects of infliximab on markers of inflammationand bone turnover and associations with bone mineraldensity in patients with ankylosing spondylitis. Ann Rheum Dis. 2009; 68: 175-82.

  33. Woo JH, Lee HJ, Sung IH, Kim TH: Changes of clinical response and bone biochemical markers in patients with ankylosing spondylitis taking etanercept. J Rheumatol. 2007; 34:1753- 59.

  34. Appel H, Janssen L, Listing J, Heydrich R, Rudwaleit M, Sieper J: Serum levels of biomarkers of bone and cartilage destructionand new bone formation in different cohorts of patients withaxial spondyloarthritis with and without tumor necrosis factoralphablocker treatment. Arthritis Res Ther. 2008; 10: 125-36.




2020     |     www.medigraphic.com